Scientists discover a 'master key' to unlock new treatments for autoimmune disorders

September 29, 2011

Imagine a single drug that would treat most, if not all, autoimmune disorders, such as asthma, inflammatory bowel disease, and Lupus. That might not be so hard to do thanks to a team of researchers who have discovered a molecule normally used by the body to prevent unnecessary immune reactions. This molecule, pronounced "alpha v beta 6," normally keeps our immune systems from overreacting when food passes through our bodies, and it may be the key that unlocks entirely new set of treatments for autoimmune disorders. This discovery was recently published in research report appearing the Journal of Leukocyte Biology.

"Currently we do not have special methods to radically treat most immune diseases; all we can do is to temporarily inhibit the clinical symptoms for those diseases," said Ping-Chang Yang, a researcher involved in the work from the Department of Pathology and at McMaster University in Ontario, Canada. "Our findings have the potential to repair the compromised immune tolerant system so as to lead the body immune system to 'correct' the ongoing pathological conditions by itself."

Scientists made this discovery in mice when they noticed that their intestines secreted alphavbeta6, when absorbing food. Alphavbeta6, together with the absorbed food, induced the body to produce immune tolerant cells, which ensured that the food did not cause an excessive . Researchers then generated alphavbeta6 using cultured and found that both could be used to generate the immune tolerant cells needed to reduce or eliminate out-of-control immune reactions.

"Development of new treatments and cures for diseases is usually a long process involving a series of incremental steps taken from the laboratory all the way through to the patient's bedside," said John Wherry, Ph.D., Deputy Editor of the . "Occasionally, however, scientists make large leaps forward instead. While considerable work remains to determine whether or not this discovery will directly translate into new therapies, the alphavbeta6 discovery reported by these scientists is exciting, if not stunning."

More information: Xiao Chen, Chun-Hua Song, Bai-Sui Feng, Tong-Li Li, Ping Li, Peng-Yuan Zheng, Xian-Ming Chen, Zhou Xing, and Ping-Chang Yang. Intestinal epithelial cell-derived integrin αβ6 plays an important role in the induction of regulatory T cells and inhibits an antigen-specific Th2 response. J Leukoc Biol. 2011 90:751-759; doi:10.1189/jlb.1210696

Related Stories

Recommended for you

A cheaper, high-performance prosthetic knee

July 30, 2015

In the last two decades, prosthetic limb technology has grown by leaps and bounds. Today, the most advanced prostheses incorporate microprocessors that work with onboard gyroscopes, accelerometers, and hydraulics to enable ...

Crystal clear images uncover secrets of hormone receptors

July 31, 2015

Many hormones and neurotransmitters work by binding to receptors on a cell's exterior surface. This activates receptors causing them to twist, turn and spark chemical reactions inside cells. NIH scientists used atomic level ...

Flow means 'go' for proper lymph system development

July 27, 2015

The lymphatic system provides a slow flow of fluid from our organs and tissues into the bloodstream. It returns fluid and proteins that leak from blood vessels, provides passage for immune and inflammatory cells from the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.